Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DUB8X2
|
|||
| Drug Name |
CLBS201
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Diabetic kidney disease [ICD-11: GB61.Z] | Phase 1 | [1] | |
| Company |
Caladrius Biosciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04990427) A Phase 1 Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of CLBS201 Autologous Peripheral Blood-Derived CD34+ Cells in Subjects With Chronic Kidney Disease and Type 2 Diabetes Mellitus. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.